Nootropics Use in the Workplace: Psychiatric and Ethical Aftermath Towards the New Frontier of Bioengineering

Total Page:16

File Type:pdf, Size:1020Kb

Nootropics Use in the Workplace: Psychiatric and Ethical Aftermath Towards the New Frontier of Bioengineering European Review for Medical and Pharmacological Sciences 2020; 24: 2129-2139 Nootropics use in the workplace: psychiatric and ethical aftermath towards the new frontier of bioengineering S. ZAAMI1, R. RINALDI1, G. BERSANI2, A. DEL RIO1, C. CIALLELLA1, E. MARINELLI1 1Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Departmental Section of Legal Medicine, “Sapienza” University of Rome, Rome, Italy 2Department of Medico-Surgical Sciences and Biotechnologies, “Sapienza” University of Rome, Rome, Italy Abstract. – OBJECTIVE: The authors have Key Words: sought to expound upon and shed a light on the Nootropics, Human Enhancement, Productivity, rise of nootropics, which have gradually taken Workplace, Bioengineering, Ethics. on a more and more relevant role in workplaces and academic settings. MATERIALS AND METHODS: Multidisciplinary Introduction databases have been delved into by entering the following keys: “nootropics”, “cognitive enhance- ment”, “workplace”, “productivity”, “ethics”, “bio- The use of therapeutic drugs for non-medical engineering”. In addition, a broad-ranging search reasons as cognitive enhancers has been spreading has been undertaken on institutional websites in and its risks seem to have become at least in part order to identify relevant analysis and recommen- acceptable among students and certain groups of dations issued by international institutions and workers. Considering the ever more competitive agencies. Papers and reports have been inde- pendently pored over by each author. This search nature of modern societies, which reverberates on strategy has led to the identification of 988 sourc- workplaces as well, enhancers are reasonably ex- es but only 64 were considered appropriate for the pected to spread even more over time; nonetheless, purposes of the paper after being selected by at long-term consequences arising from their becom- least 3 of the authors, independently. ing mainstream “supplements”, for the purpose of RESULTS: The notion of an artificially en- boosting performance, are as yet unknown. Cog- hanced work performance – carried out by the ‘superworker’ – is particularly noteworthy and nitive enhancers, used by healthy individuals, are resonates with the conception of contempo- widely known as nootropics: drugs, supplements, rary work on so many different levels: the rising and other substances that may improve cogni- need and demands for higher degrees of flex- tive function, particularly executive functions, ibility and productivity on the job, the implica- strengthening memory, creativity or even moti- tions of a ‘24/7’ society, where more and more vation in healthy individuals who choose to use services are available at any time, the ever great- them in an effort to take their performances “to the er emphasis on entrepreneurial spirit, individu- al self-reliance and self-improvement, and last next level”. The word “nootropic” was coined in but not least, the impact of an ageing society on 1972 by a Romanian scientist, Corneliu Giurgea, economic standards and performance. who combined the Greek words for “mind” and CONCLUSIONS: Moreover, it is worth men- “bending”1-3. The pharmaceutical substances and tioning that human enhancement technologies compounds known as ‘cognitive-enhancers’ can will predictably and increasingly go hand in hand allegedly boost mental performance, the ability to with gene editing, bioengineering, cybernetics 4 and nanotechnology. Applications are virtually focus and keep concentration . In broader terms, boundless, and may ultimately affect all human such drugs are often claimed to heighten and foster traits (physical strength, endurance, vision, in- motor capabilities, affective skills, (i.e., one’s abili- telligence and even personality and mood). ty to deal with anxiety stemming from performing Corresponding Authors: Raffaella Rinaldi, MD; e-mail: [email protected] 2129 S. Zaami, R. Rinaldi, G. Bersani, A. Del Rio, C. Ciallella, E. Marinelli certain work tasks or eliciting feelings of trust and levels11. Adderall (trade name) is a mixture of am- affiliation) and are available for clinical and thera- phetamine salts. It is reportedly used off-label for peutic reasons5. the purpose of increasing focus (among workers Furthermore, stagnant economic conditions and students, in particular) or to get a “high” (a certainly play a role in incentivizing worker com- strong, pleasing feeling of euphoria, typical of petition, within which some may feel compelled to recreational drugs)12. Users have shown a tenden- consider substances to enhance their productivity. cy towards polydrug use and at times, adulter- In fact, the key factor accounting for nootropics ants such as caffeine and phentermine have been use in the workplace is productivity, as measu- found added to the amphetamines13,14. Polydrug red by the amount of work produced per working use, which involves countless substances that are hour, i.e., one of the main drivers of long-term eco- extremely hard to identify and regulate, is a seri- nomic growth and higher living standards6. As a ous threat that is bound to grow as online illicit matter of fact, since the crippling 2008 economic market avenues become ever more accessible. For crisis, productivity has lagged behind pre-crisis that reason, some have called for more invest- levels, with little or no significant steady growth7. ments in toxicological and forensic analytical data Productivity growth goes hand in hand with eco- facilities and better international coordination in nomic growth and development; hence the recent order to tackle that issue15. As for the enhancing slowdown in aggregate labour productivity in le- capabilities of amphetamines, a 2014 systematic ading economies has been widely characterized review has found that low doses of amphetamine as a puzzle, even paradox. Still, viewing pharma- could potentially foster memory consolidation cological enhancers as a relatively easy shortcut and retention of information in healthy youth, as towards greater productivity entails significant well as enhance task saliency (motivation to per- medical and ethical challenges8. form a task) and execution of tedious tasks requir- ing substantial effort16,17. Cognitive Enhancers Used Off-Label: What About Safety and Effectiveness? A Widely Used Central Nervous System It is worth noting, however, that no drugs are Stimulant: Methylphenidate licensed by medical authorities to be recommend- Methylphenidate (marketed und er the brand ed and prescribed as ‘cognitive enhancers’ as names Ritalin, Equasym, Concerta, Rubifenis such. Thus, the definition ‘performance-enhanc- and Medikinet) acts as a stimulant of the central ing drug’ is usually linked to the off-label use of nervous system (CNS)18; its main application is drugs prescribed for specific medical conditions treating ADHD and narcolepsy. It raises levels of by healthy individuals, for the purposes of per- the neurotransmitters dopamine and norepineph- formance enhancement; modafinil9, used for the rine19. At above optimal doses, methylphenidate treatment of narcolepsy, or methylphenidate10, reportedly causes off-target effects negatively af- for Attention Deficit Hyperactivity Disorder fecting learning skills20. Adverse side-effects are (ADHD), fall within that category. Users acquire a cause for concern: the dopaminergic activity of such medicines on the internet, or through some- methylphenidate may lead to euphoria and addic- one who does have a prescription. Such dynamics tion (its mode of dopaminergic action is similar to mark a cultural shift in drug abuse dynamics: they that of cocaine). Methylphenidate can reportedly are in fact free of the stigma usually associated exacerbate existing behavioral problems and cen- with street drugs while also appearing safer, al- tral nervous system disorders such as bipolar dis- though there can be no certainty as to their actual ease and psychosis; its peripheral effects should composition and nature; potential dangers are not not be overlooked: higher adrenaline concentra- as clearly perceived, since the term “medicine” is tions in plasma may in fact cause or worsen heart associated with treatment and cure. problems. Hence, methylphenidate is contraindi- cated for patients with high blood pressure, heart A Broad-Ranging (and Growing) Array of defects or a family history of heart problems21. Substances: Amphetamines Several pharmaceutical drugs which are com- Atomoxetine Hydrochloride Greater monly associated with cognitive enhancing (Ta- Alertness and Focus at What Cost? ble I): ≤ Atomoxetine hydrochloride is licensed for Amphetamines, which are stimulants used to the treatment of ADHD in children of six years treat ADHD or narcolepsy, heighten dopamine and older, in children over the age of six and in 2130 Nootropics use in the workplace Table I. Principal pharmacological active substances used as nootropics and performance enhancers, their mechanism of action, therapeutic indications and side effects. Chemical Brand Mechanism Therapeutic Drug Class Side effects name name of action indications Agitation, Dopamine reuptake ADHD*, anxiety, bladder Amphetamine Stimulant Adderall inhibitor; dopamine Narcolepsy pain, depression, releaser nervousness Dopamine and Ritalin, Anxiety/ noradrenaline Equasym, nervousness, reuptake inhibitor, ADHD*, Methylphenidate Stimulant Concerta, insomnia , appetite dopaminergic and Narcolepsy Rubifenis loss, dry mouth, noradrenergic Medikinet nausea, activity stimulant Nausea, vomiting, insomnia,
Recommended publications
  • Neuroenhancement in French and Romanian University Students, Motivations and Associated Factors
    International Journal of Environmental Research and Public Health Article Neuroenhancement in French and Romanian University Students, Motivations and Associated Factors Irina Brumboiu 1, Alessandro Porrovecchio 2, Thierry Peze 2 , Remy Hurdiel 2, Irina Cazacu 1 , Cristina Mogosan 1 , Joel Ladner 3 and Marie-Pierre Tavolacci 4,* 1 Cluj-Napoca Unit—The Net-Work of International Francophone Clinical Epidemiology, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania; [email protected] (I.B.); [email protected] (I.C.); [email protected] (C.M.) 2 Univ. Littoral Côte d’Opale, Univ. Lille Artois ULR 7369—URePSSS—Unité de Recherche Pluridiscipli-Naire Sport Santé Société, F-59375 Dunkerque, France; [email protected] (A.P.); [email protected] (T.P.); [email protected] (R.H.) 3 Clinical Investigation Center 1404 and INSERM 1073, Rouen University Hospital and Rouen Normandie University, 76000 Rouen, France; [email protected] 4 Department of Epidemiology and Health Promotion and INSERM 1073, Rouen University Hospital and Rouen Normandie University, 76000 Rouen, France * Correspondence: [email protected] Abstract: This cross-sectional study aimed to determine the use of neuroenhancers, the motivations and factors associated with their use in French and Romanian university students. Students from two universities in France (Rouen and Opal Coast University) and one in Romania (Cluj-Napoca) were asked to complete a self-administered anonymous questionnaire, either online or on paper, about the use of three different categories of substance: Prescription drugs (methylphenidate, modafinil, and Citation: Brumboiu, I.; Porrovecchio, beta-blockers), drugs of abuse (alcohol, cannabis, cocaine, and amphetamines), and soft enhancers A.; Peze, T.; Hurdiel, R.; Cazacu, I.; (coffee, vitamins, caffeine tablets, and energy drinks).
    [Show full text]
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Nootropics: Boost Body and Brain? Report #2445
    NOOTROPICS: BOOST BODY AND BRAIN? REPORT #2445 BACKGROUND: Nootropics were first discovered in 1960s, and were used to help people with motion sickness and then later were tested for memory enhancement. In 1971, the nootropic drug piracetam was studied to help improve memory. Romanian doctor Corneliu Giurgea was the one to coin the term for this drug: nootropics. His idea after testing piracetam was to use a Greek combination of “nous” meaning mind and “trepein” meaning to bend. Therefore the meaning is literally to bend the mind. Since then, studies on this drug have been done all around the world. One test in particular studied neuroprotective benefits with Alzheimer’s patients. More tests were done with analogues of piracetam and were equally upbeat. This is a small fraction of nootropic drugs studied over the past decade. Studies were done first on animals and rats and later after results from toxicity reports, on willing humans. (Source: https://www.purenootropics.net/general-nootropics/history-of-nootropics/) A COGNITIVE EDGE: Many decades of tests have convinced some people of how important the drugs can be for people who want an enhancement in life. These neuro-enhancing drugs are being used more and more in the modern world. Nootropics come in many forms and the main one is caffeine. Caffeine reduces physical fatigue by stimulating the body’s metabolism. The molecules can pass through the blood brain barrier to affect the neurotransmitters that play a role in inhibition. These molecule messengers can produce muscle relaxation, stress reduction, and onset of sleep. Caffeine is great for short–term focus and alertness, but piracetam is shown to work for long-term memory.
    [Show full text]
  • Nootropic Concepts
    Nootropic concepts intelligent ingredient for gut health Nootropics definition Nootropic is a substance that enhances cognition and memory and facilitates learning. Nootropics work in many ways to produce a range of benefits across memory, focus, attention, motivation, relaxation, mood, alertness, stress resistance. Bluenesse® Bluenesse® – an innovative, exclusive lemon balm extract, Melissa officinalis (L.) – supports your mental health. It has an immediate effect on focus, concentration, and memory. Furthermore, it supports a calm and good mood and helps to balance the stress hormone cortisol. Bluenesse® - Nootropics concepts Nootropic benefits of Bluenesse® and the underlying mode of action: Bluenesse® - Nootropics concepts – detailed information: Several, double blind, randomized, placebo-controlled, crossover human study results have shown that Bluenesse® supports nootropic effects on demand. Below, the investigated parameter and mode of action is explained per each nootropic application. Vital Solutions GmbH, Hausingerstrasse 6, D-40764 Langenfeld, +49 (0) 2173 109 82 02 [email protected] www.vitalsolutions.biz . Nootropic concepts Cognitive performance support and enhancing learning & memory: Bluenesse® significantly improves cognitive performance, particularly alertness, working memory and mathematic processing by improving the efficiency of neuronal communication. It activates Muscarinic receptors, which are responsible for the efficient flow of information between neurological cells, so-called “oscillation”, leading to
    [Show full text]
  • Treatment Protocol Copyright © 2018 Kostoff Et Al
    Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Diagnostic and Prognostic Advances in Pediatric Mild Traumatic Brain Injury
    Diagnostic and Prognostic Advances in Pediatric Mild Traumatic Brain Injury Lynn Babcock, MD, MS Division of Pediatric Emergency Medicine CME Disclosure Statement Lynn Babcock, MD, MS • I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity. • I do not intend to discuss an unapproved or investigative use of a commercial product/device in my presentation. Learning Objectives 1. Implement current diagnostic and prognostic methods for children with mild TBI. 2. Understand how serum biomarkers aid in the diagnosis and prognosis of children with mild TBI. 3. Appreciate advanced neuroimaging as a diagnostic and prognostic tool for children with mild TBI. Case 9 year old boy is playing hockey. Helmeted. Is chasing after the puck, gets tripped (of course accidently) and then gets pile driven into the boards by a much larger 10 year old. He appears unresponsive for a about 1 minute, then he starts to cry. He is unable to get up, and then is helped off the ice. He is dazed and confused for about 5 minutes. His parents bring him into ED. Parents ask: Does he have a brain injury? When can he go back into the game? Primary Injury • “Focal” injuries • “Diffuse” injuries – Direct mechanical damage – Rotational forces critical – Impact – Acceleration, deceleration – Acceleration, deceleration – Results: – Results: • Axonal stretch à axotomy • Coup/counter coup • Primary axotomy • Hemorrhage/infarction • Microhemorrhages • Rapid oncotic injury
    [Show full text]
  • Modafinil and Modafinil Analogues: Free Radical Mechanism of the Eugeroic and Cognitive Enhancment Effect Clifford Fong
    Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford Fong To cite this version: Clifford Fong. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect. [Research Report] Eigenenergy. 2018. hal-01933737 HAL Id: hal-01933737 https://hal.archives-ouvertes.fr/hal-01933737 Submitted on 24 Nov 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford W. Fong Eigenenergy, Adelaide, South Australia. Keywords: Modafinil, modafinil-like analogues, eugeroic effect, cognitive enhancement, free radicals, quantum mechanics Abbreviations Dopamine DA, dopamine transporter DAT, Dissociative electron transfer or attachment DET, Linear free energy relationship LFER, free energy of water desolvation ΔG desolv,CDS , lipophilicity free energy ΔG lipo,CDS, cavity dispersion solvent structure of the first solvation shell CDS, highest occupied molecular orbital HOMO, lowest unoccupied molecular orbital LUMO, multiple correlation coefficient R 2, the F test of significance, standards errors for the estimate (SEE) and standard errors of the variables SE(ΔG desolCDS ), SE(ΔG lipoCDS ), SE(Dipole Moment), SE (Molecular Volume), transition state TS, reactive oxygen species ROS.
    [Show full text]
  • Patterns Of, and Motivations for Illicit Drug Use Among Long Haul
    Fatigue and beyond: Patterns of, and motivations for illicit drug use among long haul truck drivers Naomi Richards BPsych (Hons) This thesis is submitted for the degree of Masters of Applied Science (Research) within the Centre for Accident Research and Road Safety-Queensland (CARRS-Q), School of Psychology and Counselling, Queensland University of Technology 2004 Key words Drug use Drug use career Illicit drug use Road safety Truck drivers Abstract Long distance truck drivers are considered a special interest group in terms of drug driving research and policy due to high rates of use, involvement of drugs in truck accidents and the link between drug use and work related fatigue. Qualitative interview data was collected from 35 long haul truck drivers in South East Queensland and analysed using NVivo 2.0. High rates of licit and illicit drug use (particularly amphetamines) were reported. However, unlike previous studies which focus on fatigue, this research found overlapping and changing motivations for drug use during individual lifetimes. Using Becker’s model of a drug use ‘career’ it was revealed that some drivers begin illicit drug use before they begin truck driving. As well as fatigue, powerful motives such as peer pressure, wanting to fit the trucking ‘image’, socialisation, relaxation and addiction were reported. These may need to be considered along side fatigue in the development of effective drug prevention or cessation policies for truck drivers. Contents Page 1. Introduction 1 2. Literature Review 5 2.1. Drugs of concern to road safety 5 2.1.1. Cannabis 6 2.1.1.1. Effects of cannabis on driving performance 7 2.1.2.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Aniracetam Reduces Glutamate Receptor Desensitization and Slows
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 10936-10940, December 1991 Neurobiology Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus (non-N-methyl-D-aspartate receptor/synapse) JEFFRY S. ISAACSON*t AND ROGER A. NICOLLtt *Physiology Graduate Program and the Departments of SPharmacology and tPhysiology, University of California, San Francisco, CA 94143-0450 Communicated by Floyd E. Bloom, September 16, 1991 ABSTRACT Aniracetam is a nootropic drug that has been and DL-2-amino-5-phosphonovaleric acid (50 ,uM) were shown to selectively enhance quisqualate receptor-mediated added to the medium to block y-aminobutyric acid type A responses inXenopus oocytes injected with brain mRNA and in (GABAA) receptors and NMDA receptors, respectively. In hippocampal pyramidal cells [Ito, I., Tanabe, S., Kohda, A. & the majority of experiments examining iontophoretic re- Sugiyama, H. (1990) J. Physiol. (London) 424, 533-544]. We sponses, tetrodotoxin (0.5-1 1uM) was included to block have used patch clamp recording techniques in hippocampal sodium-dependent action potentials. Currents were recorded slices to elucidate the mechanism for this selective action. We with an Axopatch 1B amplifier from neurons in the CA1 and find that aniracetam enhances glutamate-evoked currents in CA3 pyramidal cell layers and granule cell layer of the whole-cell recordings and, in outside-out patches, strongly dentate gyrus using the "blind" whole-cell recording tech- reduces glutamate receptor desensitization. In addition, nique (15, 16). Patch electrodes (tip diameter = 2 Ium) aniracetam selectively prolongs the time course and increases contained (in mM) either a CsF (110 CsF, 10 CsCl, 10 Hepes, the peak amplitude of fast synaptic currents.
    [Show full text]